Cyfuse Biomedical KK (FSE:4892) Long-Term Debt: 円642.34 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FSE:4892 Cyfuse Biomedical KK FSE:4892
31 GF Score
Price 円527.00
GF Value 円2,172.95
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Cyfuse Biomedical KK Long-Term Debt?

Cyfuse Biomedical KK FSE:4892 31 Long-Term Debt is 円642.34 Mil as of Dec. 2025. GuruFocus rates FSE:4892 with a GF Score™ of 31/100 and a GF Value™ of 円2,172.95 (Possible Value Trap). The stock has 5 warning signs investors should review.

Cyfuse Biomedical KK's Long-Term Debt for the quarter that ended in Dec. 2025 was 円642.34 Mil.

Cyfuse Biomedical KK's quarterly Long-Term Debt increased from Jun. 2025 (円318.00 Mil) to Sep. 2025 (円771.83 Mil) but then declined from Sep. 2025 (円771.83 Mil) to Dec. 2025 (円642.34 Mil).

Cyfuse Biomedical KK's annual Long-Term Debt declined from Dec. 2023 (円345.00 Mil) to Dec. 2024 (円327.00 Mil) but then increased from Dec. 2024 (円327.00 Mil) to Dec. 2025 (円642.34 Mil).

Cyfuse Biomedical KK  (FSE:4892) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Cyfuse Biomedical KK Long-Term Debt Related Terms

Cyfuse Biomedical KK Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Cyfuse Biomedical KK's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyfuse Biomedical KK Long-Term Debt Chart

Cyfuse Biomedical KK Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial 359.82 363.00 345.00 327.00 642.34

Cyfuse Biomedical KK Quarterly Data
Dec20 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 322.50 318.00 771.83 642.34 512.84
FSE:4892
31GF Score
Cyfuse Biomedical KK FSE:4892
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of 円642.34 Mil mean?
Cyfuse Biomedical KK (FSE:4892) has a Long-Term Debt of 円642.34 Mil as of Dec. 2025.
Is Cyfuse Biomedical KK's Long-Term Debt too high?
Cyfuse Biomedical KK's current Long-Term Debt is 円642.34 Mil. Overall, Cyfuse Biomedical KK has a GF Score™ of 31/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyfuse Biomedical KK's Long-Term Debt compare to ?
Cyfuse Biomedical KK's Long-Term Debt of 円642.34 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Cyfuse Biomedical KK's current Long-Term Debt is 円642.34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyfuse Biomedical KK stock overvalued right now?
Based on GuruFocus' analysis, Cyfuse Biomedical KK (FSE:4892) is currently considered Possible Value Trap. The stock's GF Value™ is 円2,172.95, compared to a current price of 円527.00 — trading 75.7% below its estimated fair value. The current Long-Term Debt is 円642.34 Mil. Cyfuse Biomedical KK's overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Cyfuse Biomedical KK (FSE:4892), the current Long-Term Debt is 円642.34 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cyfuse Biomedical KK (FSE:4892) Overvalued in 2026?

Based on GuruFocus' analysis, Cyfuse Biomedical KK stock appears to be undervalued. The current stock price of 円527.00 is trading 75.7% below its estimated GF Value™ of 円2,172.95. GuruFocus considers Cyfuse Biomedical KK to be Possible Value Trap.

Key valuation signals for FSE:4892:

  • Long-Term Debt: 円642.34 Mil
  • GF Value™: 円2,172.95 vs. price of 円527.00 (75.7% below fair value)
  • GF Score™: 31/100 with 5 warning signs

No single metric tells the full story. See the FSE:4892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cyfuse Biomedical KK Business Description

Comparable Companies
Address 3-5-27 Mita, 1st Floor, Sumitomo Real Estate Tokyo Mita South Tower, Minato-ku, Tokyo, JPN, 108-6301
Cyfuse Biomedical KK is engaged in the development, manufacturing, and sales of regenerative medicine-related products. The company focuses on delivering three-dimensional tissues and organs created solely from cells as new 3D cell products to medical fields, including regenerative medicine and drug discovery, through the practical application of three-dimensional cell stacking technology. It is engaged in multifaceted development in the following areas: regenerative medicine, drug discovery support, and the device domain, including the development and sales of 3D cell stacking system equipment, such as bio 3D printers equipped with the company's platform technology.
31GF Score

Get the complete analysis for FSE:4892

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円527.00
Price
円2,172.95
GF Value